Effectiveness of a Serogroup B Outer Membrane Vesicle Meningococcal Vaccine Against Gonorrhoea: a Retrospective Observational Study

Overview

Journal Lancet Infect Dis

Specialty Infectious Diseases

Date 2022 Apr 15

PMID 35427490

Authors

Winston E Abara

Kyle T Bernstein

Felicia M T Lewis

Julia A Schillinger

Kristen Feemster

Preeti Pathela

Susan Hariri

Aras Islam

Michael Eberhart

Iris Cheng

Alexandra Ternier

Jennifer Sanderson Slutsker

Sarah Mbaeyi

Robbie Madera

Robert D Kirkcaldy

Affiliations

Soon will be listed here.

Abstract

Background: Declining antimicrobial susceptibility to current gonorrhoea antibiotic treatment and inadequate treatment options have raised the possibility of untreatable gonorrhoea. New prevention approaches, such as vaccination, are needed. Outer membrane vesicle meningococcal serogroup B vaccines might be protective against gonorrhoea. We evaluated the effectiveness of a serogroup B meningococcal outer membrane vesicle vaccine (MenB-4C) against gonorrhoea in individuals aged 16-23 years in two US cities.

Methods: We identified laboratory-confirmed gonorrhoea and chlamydia infections among individuals aged 16-23 years from sexually transmitted infection surveillance records in New York City and Philadelphia from 2016 to 2018. We linked gonorrhoea and chlamydia case records to immunisation registry records to determine MenB-4C vaccination status at infection, defined as complete vaccination (two MenB-4C doses administered 30-180 days apart), partial vaccination (single MenB-4C vaccine dose), or no vaccination (serogroup B meningococcal vaccine naive). Using log-binomial regression with generalised estimating equations to account for correlations between multiple infections per patient, we calculated adjusted prevalence ratios (APR) and 95% CIs to determine if vaccination was protective against gonorrhoea. We used individual-level data for descriptive analyses and infection-level data for regression analyses.

Findings: Between Jan 1, 2016, and Dec 31, 2018, we identified 167 706 infections (18 099 gonococcal infections, 124 876 chlamydial infections, and 24 731 gonococcal and chlamydial co-infections) among 109 737 individuals linked to the immunisation registries. 7692 individuals were vaccinated, of whom 4032 (52·4%) had received one dose, 3596 (46·7%) two doses, and 64 (<1·0%) at least three doses. Compared with no vaccination, complete vaccination series (APR 0·60, 95% CI 0·47-0·77; p<0·0001) and partial vaccination series (0·74, 0·63-0·88; p=0·0012) were protective against gonorrhoea. Complete MenB-4C vaccination series was 40% (95% CI 23-53) effective against gonorrhoea and partial MenB-4C vaccination series was 26% (12-37) effective.

Interpretation: MenB-4C vaccination was associated with a reduced gonorrhoea prevalence. MenB-4C could offer cross-protection against Neisseria gonorrhoeae. Development of an effective gonococcal vaccine might be feasible with implications for gonorrhoea prevention and control.

Funding: None.

Citing Articles

Human Factor H and anti-Neisserial surface protein A (NspA) antibodies compete for overlapping binding sites on meningococcal NspA.

Raghunathan D, Lim S, Moe G, Beernink P Infect Immun. 2025; 93(3):e0033924.

PMID: 39992115 PMC: 11895441. DOI: 10.1128/iai.00339-24.

Meningococcal Vaccination in the United States: Past, Present, And Future.

Schillie S, McNamara L Paediatr Drugs. 2025; .

PMID: 39979767 DOI: 10.1007/s40272-024-00666-2.

Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post-Program Implementation: Observational Case-Control Study.

Wang B, Giles L, Andraweera P, McMillan M, Beazley R, Sisnowski J Open Forum Infect Dis. 2025; 12(1):ofae726.

PMID: 39877397 PMC: 11774120. DOI: 10.1093/ofid/ofae726.

From Cure to Prevention: Doxycycline's Potential in Prophylaxis for Sexually Transmitted Infections.

Bird J, Alawyia B, Spernovasilis N, Alon-Ellenbogen D Antibiotics (Basel). 2025; 13(12.

PMID: 39766573 PMC: 11672461. DOI: 10.3390/antibiotics13121183.

A systematic review to identify research gaps in studies modeling MenB vaccinations against Neisseria infections.

Metelmann S, Thompson A, Donten A, Oke S, Sun S, Borrow R PLoS One. 2025; 20(1):e0316184.

PMID: 39746102 PMC: 11694989. DOI: 10.1371/journal.pone.0316184.

References

Vonck R, Darville T, OConnell C, Jerse A . Chlamydial infection increases gonococcal colonization in a novel murine coinfection model. Infect Immun. 2011; 79(4):1566-77. PMC: 3067530. DOI: 10.1128/IAI.01155-10. View

Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F . Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017; 390(10102):1603-1610. DOI: 10.1016/S0140-6736(17)31449-6. View

St Cyr S, Barbee L, Workowski K, Bachmann L, Pham C, Schlanger K . Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(50):1911-1916. PMC: 7745960. DOI: 10.15585/mmwr.mm6950a6. View

Rajeeve K, Das S, Prusty B, Rudel T . Chlamydia trachomatis paralyses neutrophils to evade the host innate immune response. Nat Microbiol. 2018; 3(7):824-835. DOI: 10.1038/s41564-018-0182-y. View

Flacco M, Manzoli L, Rosso A, Marzuillo C, Bergamini M, Stefanati A . Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis. Lancet Infect Dis. 2018; 18(4):461-472. DOI: 10.1016/S1473-3099(18)30048-3. View

Craig A, Gray R, Edwards J, Apicella M, Jennings M, Wilson D . The potential impact of vaccination on the prevalence of gonorrhea. Vaccine. 2015; 33(36):4520-4525. PMC: 4743649. DOI: 10.1016/j.vaccine.2015.07.015. View

Abara W, Llata E, Schumacher C, Carlos-Henderson J, Peralta A, Huspeni D . Extragenital Gonorrhea and Chlamydia Positivity and the Potential for Missed Extragenital Gonorrhea With Concurrent Urethral Chlamydia Among Men Who Have Sex With Men Attending Sexually Transmitted Disease Clinics-Sexually Transmitted Disease.... Sex Transm Dis. 2020; 47(6):361-368. PMC: 10207946. DOI: 10.1097/OLQ.0000000000001170. View

Unemo M, Shafer W . Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014; 27(3):587-613. PMC: 4135894. DOI: 10.1128/CMR.00010-14. View

Abara W, Kirkcaldy R, Bernstein K, Zlotorzynska M, Sanchez T . Acceptability of a Gonococcal Vaccine Among Sexually Active Men Who Have Sex With Men. Sex Transm Dis. 2021; 49(1):76-80. PMC: 10207945. DOI: 10.1097/OLQ.0000000000001510. View

10.

Mbaeyi S, Bozio C, Duffy J, Rubin L, Hariri S, Stephens D . Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2021; 69(9):1-41. PMC: 7527029. DOI: 10.15585/mmwr.rr6909a1. View

11.

Giuntini S, Lujan E, Gibani M, Dold C, Rollier C, Pollard A . Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci. Clin Vaccine Immunol. 2016; 24(1). PMC: 5216433. DOI: 10.1128/CVI.00430-16. View

12.

Santolaya M, ORyan M, Valenzuela M, Prado V, Vergara R, Munoz A . Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012; 379(9816):617-24. DOI: 10.1016/S0140-6736(11)61713-3. View

13.

Lujan E, Winter K, Rovaris J, Liu Q, Granoff D . Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus. Clin Infect Dis. 2017; 65(7):1112-1119. PMC: 5850644. DOI: 10.1093/cid/cix519. View

14.

Abara W, Jerse A, Hariri S, Kirkcaldy R . Planning for a Gonococcal Vaccine: A Narrative Review of Vaccine Development and Public Health Implications. Sex Transm Dis. 2020; 48(7):453-457. PMC: 10170965. DOI: 10.1097/OLQ.0000000000001332. View

15.

Semchenko E, Tan A, Borrow R, Seib K . The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae. Clin Infect Dis. 2018; 69(7):1101-1111. PMC: 6743822. DOI: 10.1093/cid/ciy1061. View

16.

Santolaya M, ORyan M, Valenzuela M, Prado V, Vergara R, Munoz A . Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother. 2013; 9(11):2304-10. PMC: 3981837. DOI: 10.4161/hv.25505. View

17.

Tinsley C, Nassif X . Analysis of the genetic differences between Neisseria meningitidis and Neisseria gonorrhoeae: two closely related bacteria expressing two different pathogenicities. Proc Natl Acad Sci U S A. 1996; 93(20):11109-14. PMC: 38292. DOI: 10.1073/pnas.93.20.11109. View

18.

Whelan J, Klovstad H, Haugen I, Robert-Du Ry van Beest Holle M, Storsaeter J . Ecologic Study of Meningococcal B Vaccine and Neisseria gonorrhoeae Infection, Norway. Emerg Infect Dis. 2016; 22(6):1137-9. PMC: 4880101. DOI: 10.3201/eid2206.151093. View

19.

Ladhani S, Andrews N, Parikh S, Campbell H, White J, Edelstein M . Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. N Engl J Med. 2020; 382(4):309-317. DOI: 10.1056/NEJMoa1901229. View

20.

Whittles L, White P, Didelot X . Assessment of the Potential of Vaccination to Combat Antibiotic Resistance in Gonorrhea: A Modeling Analysis to Determine Preferred Product Characteristics. Clin Infect Dis. 2020; 71(8):1912-1919. PMC: 7643747. DOI: 10.1093/cid/ciz1241. View